Friday’s update: Michigan’s daily new case count continues to rise – Grand Haven Tribune

The state health department on Friday reported 8,058 new confirmed cases of the coronavirus and 79 COVID-19-related deaths in Michigan since Wednesday’s report.

That is an average of 4,029 new cases each day, Thursday and Friday, up from the 3,386 per-day average for the previous report of Sept. 28-29 and 2,577 per day Sept. 25-27.

The state’s pandemic total number of confirmed cases is now 1,030,633, with 21,077 deaths.

The Ottawa County health department on Friday reported 268 new cases of the virus and three deaths related to COVID-19 since Wednesday. The county’s pandemic total number of cases is now 38,165, with 34,881 recovered and 469 deaths.

The level of community transmission in Ottawa County remains “high.”

Muskegon County on Friday added 182 confirmed cases of the virus and two new deaths related to COVID-19 since Wednesday’s report from the state health department. That’s an average of 91 new cases each day, down from the previous report’s 104 new cases per day, Sept. 28-29, and up from the 61 new cases each day for Sept. 25-27.

Muskegon County’s pandemic total number of confirmed cases is now 19,295, with 401 deaths.

Merck says experimental pill cuts worst effects of COVID


Lab manager Robyn Schuman holds blood samples to be tested for COVID-19 at the Bellville Medical Center in Bellville, Texas, on Sept. 1. 

WASHINGTON — In a potential leap forward in the global fight against the pandemic, drugmaker Merck said Friday that its experimental pill for people sick with COVID-19 reduced hospitalizations and deaths by half.

That could add a whole new easy-to-use weapon to an arsenal that already includes the COVID-19 vaccine.

The company said it will soon ask health officials in the U.S. and around the world to authorize the pill’s use. A decision from the U.S. Food and Drug Administration could come within weeks after that, and the drug, if it gets the OK, could be distributed quickly soon afterward.

If cleared, it would be the first pill shown to treat COVID-19. All other therapies now authorized in the U.S. require an IV or injection. A pill taken at home, by contrast, would ease pressure on hospitals and could also help curb outbreaks in poorer and more remote corners of the world that don’t have access to the more expensive infusion therapies.

“This would allow us to treat many more people much more quickly and, we trust, much less expensively,” said Dr. William Schaffner, an infectious disease expert at Vanderbilt University who was not involved in the research.

Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and death as those who received a dummy pill.

The study tracked 775 adults with mild-to-moderate COVID-19 who were considered to be at higher risk for severe disease because of health problems such as obesity, diabetes or heart disease. The results have not been reviewed by outside experts, the usual procedure for vetting new medical research.

Among patients taking molnupiravir, 7.3 percent were either hospitalized or died at the end of 30 days, compared with 14.1 percent of those getting the dummy pill. After that time period, there were no deaths among those who received the drug, compared with eight in the placebo group, according to Merck.

The results were so strong that an independent group of medical experts monitoring the trial recommended stopping it early.

Company executives said they plan to submit the data to the FDA in the coming days.

Even with the news of a potentially effective new treatment for COVID-19, experts stressed the importance of vaccines for controlling the pandemic, given that they help prevent transmission and also reduce the severity of illness in those who do get infected.

White House coronavirus coordinator Jeff Zients said that vaccination will remain the government’s main strategy for controlling the pandemic. “We want to prevent infections, not just wait to treat them when they happen,” he said.

Dr. Anthony Fauci, the government’s foremost authority on infectious diseases, called the results from Merck “very good news.”

Merck studied its drug only in people who were not vaccinated. But FDA regulators may consider authorizing it for broader use in vaccinated patients who get breakthrough COVID-19 symptoms.

Andrew Pekosz of Johns Hopkins University predicted vaccines and antiviral drugs would ultimately be used together to protect against the worst effects of COVID-19.

“These shouldn’t be seen as replacements for vaccination — the two should be seen as two strategies that can be used together to significantly reduce severe disease,” Pekosz said.

Patients take four pills twice a day for five days. Side effects were reported by both groups in the Merck trial, but they were slightly more common among those who received a dummy pill. The company did not specify the problems.

Earlier study results showed the drug did not benefit patients who were already hospitalized with severe disease.

The U.S. has approved one antiviral drug, remdesivir, specifically for COVID-19, and allowed emergency use of three antibody therapies that help the immune system fight the virus. But all the drugs have to given by IV or injection at hospitals or clinics, and supplies have been stretched by the latest surge of the delta variant.

Health experts, including Fauci, have long called for a convenient pill that patients could take when COVID-19 symptoms first appear, much the way Tamiflu is given to help fight the flu. Such medications are seen as key to controlling waves of infection.

Merck’s pill works by interfering with the coronavirus’s ability to copy its genetic code and reproduce itself.

The U.S. government has committed to purchasing enough pills to treat 1.7 million people, assuming the FDA authorizes the drug. Merck said it can produce pills for 10 million patients by the end of the year and has contracts with governments worldwide. The company has not announced prices.

Several other companies, including Pfizer and Roche, are studying similar drugs and could report results in the coming weeks and months.

Merck had planned to enroll more than 1,500 patients in its late-stage trial before the independent board stopped it early. The results reported Friday included patients across Latin America, Europe and Africa. Executives estimated 10% of patients studied were from the U.S.

Leave a Reply

Your email address will not be published. Required fields are marked *

npressfetimg-377.png Previous post “It’s painful:” Zeeland family farm in dispute with township over closed farm stand –
npressfetimg-379.png Next post Grand Haven forecast | Local News | – Grand Haven Tribune